Zacks Research Has Pessimistic Outlook of Neogen Q1 Earnings

Neogen Corporation (NASDAQ:NEOG) – Zacks Research lowered their Q1 2026 earnings estimates for Neogen in a note issued to investors on Tuesday, August 19th. Zacks Research analyst Team now forecasts that the company will earn $0.05 per share for the quarter, down from their prior estimate of $0.07. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.08 EPS, Q1 2027 earnings at $0.08 EPS and Q2 2027 earnings at $0.09 EPS.

A number of other analysts have also recently commented on the stock. William Blair cut shares of Neogen from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 29th. Guggenheim decreased their target price on shares of Neogen from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, June 30th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.50.

Neogen Stock Down 0.7%

Shares of Neogen stock opened at $5.57 on Thursday. Neogen has a 1 year low of $3.87 and a 1 year high of $17.95. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -1.11 and a beta of 1.79. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.32 and a quick ratio of 2.22. The firm’s 50-day moving average is $5.11 and its two-hundred day moving average is $6.71.

Institutional Trading of Neogen

A number of large investors have recently made changes to their positions in NEOG. Principal Financial Group Inc. grew its position in shares of Neogen by 90.3% during the first quarter. Principal Financial Group Inc. now owns 1,123,391 shares of the company’s stock worth $9,740,000 after acquiring an additional 533,064 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Neogen by 212.9% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 107,395 shares of the company’s stock valued at $931,000 after acquiring an additional 73,071 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Neogen in the fourth quarter valued at about $2,744,000. Dimensional Fund Advisors LP boosted its holdings in shares of Neogen by 24.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,939,984 shares of the company’s stock valued at $84,254,000 after acquiring an additional 1,345,056 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in shares of Neogen by 386.2% during the 1st quarter. State of Alaska Department of Revenue now owns 109,387 shares of the company’s stock valued at $948,000 after acquiring an additional 86,887 shares during the period. 96.73% of the stock is currently owned by hedge funds and other institutional investors.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.